IQVIA Holdings Inc (IQV) Stock AnalysisIQVIQVIA Holdings Inc

IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Commercial Solutions and Research & Development Solutions. Its commercial solutions provide mission critical information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the Company’s life science clients. Its research & development solutions primarily serve biopharmaceutical customers, provide outsourced clinical research, clinical trial and real-world research related services. The Company offers clinical products, commercial products, compliance, safety, reg products, real world products, and others. Its clinical products include planning suite, grant plan, site suite, clinical trial payments, investigator site portal, one home for sites, patient engagement suite and others. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

IQVIA Holdings Inc is a good buy right now due to its strong financial performance and positive market sentiment. The current price of $266.90 is below the average analyst price target of $305, suggesting a potential upside of approximately 14%. Additionally, the forward P/E ratio is 18.42, which is attractive compared to the current P/E of 32.18, indicating that the stock may be undervalued relative to its future earnings potential. However, the main risk is the insider selling, with executives reducing their holdings by 19%, which may signal caution regarding future performance.

17 analysts cover IQV: 9 rate it Buy, 8 Hold and 0 Sell. The average price target is 258.31.